Exciting Phase 3 Results for Ulcerative Colitis Treatment
Abivax, a prominent clinical-stage biotechnology company, has announced promising results from its Phase 3 ABTECT trials. These trials took a closer look at the efficacy of obefazimod, a first-in-class oral miR-124 enhancer, specifically for adults suffering from moderate to severe ulcerative colitis (UC). The results from these eight-week induction trials highlight significant advancements in treatment options for those living with UC.
Promising Outcomes from the ABTECT Trials
Throughout the ABTECT-1 and ABTECT-2 trials, a daily dose of 50 mg of obefazimod led to an impressive pooled 16.4% clinical remission rate at the eight-week mark, a statistically significant achievement (p<0.0001). Breaking it down further, ABTECT-1 alone achieved a 19.3% remission rate (p<0.0001), while ABTECT-2 reported a rate of 13.4% (p=0.0001). These findings not only meet but exceed expectations, demonstrating the potential of obefazimod as a transformative treatment.
Significance of Trial Designs
The trials were crucial in understanding the drug’s safety and efficacy across a varied patient demographic, including individuals with varying experiences with advanced therapies. Notably, nearly half (47.3%) of the trial participants had previously shown inadequate response to advanced therapies, including JAK inhibitors. This larger population approach provides a more comprehensive understanding of obefazimod's impact.
Safety Profile and Tolerability
Safety data were equally encouraging, as obefazimod demonstrated favorable tolerability with no new safety signals. The treatment was well-received across all dose groups, confirming its potential for long-term use in managing ulcerative colitis.
Future Perspectives
Looking ahead, the ABTECT Maintenance Trial is currently ongoing, and top-line results are anticipated. Among the 1,275 patients involved in the induction trials, 678 successfully achieved clinical responses and began the maintenance segment. This ongoing phase is essential for understanding the long-term benefits of obefazimod.
Regulatory Plans for Abivax
As Abivax prepares for the next steps, pending the success of the maintenance trial results, the company is moving forward with plans to submit a New Drug Application (NDA) for obefazimod to the U.S. FDA and a Marketing Authorization Application (MAA) to the EMA in the latter half of 2026. The pathway set by these ongoing studies and their results positions Abivax uniquely in the competitive landscape of UC treatments.
Experts Weigh In
Marc de Garidel, Chief Executive Officer of Abivax, expressed his excitement: “Today marks a significant milestone for Abivax, and more importantly, for the ulcerative colitis community. These results reinforce our confidence in obefazimod's potential as a transformative treatment for UC patients.”
Dr. David Rubin, a lead gastroenterologist, added, “The impressive efficacy and safety displayed in these trials offer hope for those suffering from ulcerative colitis. This innovative treatment could provide new options for patients who have struggled with existing therapies.”
Frequently Asked Questions
What is obefazimod?
Obefazimod is a first-in-class oral miR-124 enhancer being developed by Abivax for treating moderately to severely active ulcerative colitis.
What were the key findings from the ABTECT trials?
The trials indicated that a 50 mg dose of obefazimod resulted in a statistically significant clinical remission rate, achieving 16.4% at week eight when adjusted for placebo.
What side effects were reported during the trials?
The treatment showed favorable tolerability with no significant new safety signals observed in participants, demonstrating a solid safety profile.
When will the maintenance trial results be available?
Top-line results from the ABTECT Maintenance Trial are expected in the second quarter of 2026.
What are Abivax's plans following these results?
Pending successful outcomes from the maintenance trial, Abivax plans to submit both an NDA to the FDA and a MAA to the EMA by late 2026.
